STING1 and neoplasm: Lam et al. showed that microbial-derived STING agonists (c-di-AMP) enhance anti-tumor immune responses by inducing tumor-tissue monocyte-derived interferon type I (IFN-I) production, and modulating macrophage polarization and NK-DC interactions.